Nadeau Lab. Department of Environmental Health
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nadeau, Kari Christine
NCT02062814: A Phase 2 Randomized, Controlled, Blinded Study Omalizumab With Oral Food Immunotherapy in Children and Adults With Multiple Food Allergies

Active, not recruiting
2
60
US
omalizumab, xolair, Placebo
Stanford University
Immune System Disease
02/17
02/17
NCT03742414: Seal, Stopping Eczema and Allergy Study

Recruiting
2
312
Europe, US
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Kari Nadeau, MD, PhD, National Jewish Health, University of Chicago, Children's Hospital Medical Center, Cincinnati, Harvard School of Public Health (HSPH), Stanford University, National Institute of Allergy and Infectious Diseases (NIAID), King's College London, Guy's and St Thomas' NHS Foundation Trust
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
05/28
06/28
PRROTECT, NCT01781637: Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

Completed
1/2
36
US
Omalizumab, Xolair, placebo
Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University, Ann & Robert H Lurie Children's Hospital of Chicago
Peanut Allergy, Food Allergy
10/15
05/22
NCT04549142: Immune Tolerance Dysfunction in Pregnancy Due to Ambient Air Pollution Exposure

Completed
N/A
400
US
There is no intervention
Stanford University, National Institute of Environmental Health Sciences (NIEHS), Duke University
Air Pollution, Pregnancy
06/23
06/23
NCT04579588: Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Recruiting
N/A
230
US
Flu shot
Stanford University, National Institute of Allergy and Infectious Diseases (NIAID)
Corona Virus Infection, Flu Vaccine, Immunity
03/26
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nadeau, Kari Christine
NCT02062814: A Phase 2 Randomized, Controlled, Blinded Study Omalizumab With Oral Food Immunotherapy in Children and Adults With Multiple Food Allergies

Active, not recruiting
2
60
US
omalizumab, xolair, Placebo
Stanford University
Immune System Disease
02/17
02/17
NCT03742414: Seal, Stopping Eczema and Allergy Study

Recruiting
2
312
Europe, US
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Kari Nadeau, MD, PhD, National Jewish Health, University of Chicago, Children's Hospital Medical Center, Cincinnati, Harvard School of Public Health (HSPH), Stanford University, National Institute of Allergy and Infectious Diseases (NIAID), King's College London, Guy's and St Thomas' NHS Foundation Trust
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
05/28
06/28
PRROTECT, NCT01781637: Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

Completed
1/2
36
US
Omalizumab, Xolair, placebo
Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University, Ann & Robert H Lurie Children's Hospital of Chicago
Peanut Allergy, Food Allergy
10/15
05/22
NCT04549142: Immune Tolerance Dysfunction in Pregnancy Due to Ambient Air Pollution Exposure

Completed
N/A
400
US
There is no intervention
Stanford University, National Institute of Environmental Health Sciences (NIEHS), Duke University
Air Pollution, Pregnancy
06/23
06/23
NCT04579588: Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Recruiting
N/A
230
US
Flu shot
Stanford University, National Institute of Allergy and Infectious Diseases (NIAID)
Corona Virus Infection, Flu Vaccine, Immunity
03/26
03/26

Download Options